Antineoplastic Agents Clinical Trials

8 recruitingLast updated: June 17, 2026

There are 8 actively recruiting antineoplastic agents clinical trials across 5 countries. Studies span Not Applicable, Phase 1, Phase 2. Top locations include Amiens, France, Annecy, France, Aurillac, France. Updated daily from ClinicalTrials.gov.


Antineoplastic Agents Trials at a Glance

8 actively recruiting trials for antineoplastic agents are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Amiens, Annecy, and Aurillac. Lead sponsors running antineoplastic agents studies include Fondazione Ricerca e Innovazione Cardiovascolare ETS, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, and Federation Francophone de Cancerologie Digestive.

Browse antineoplastic agents trials by phase

Treatments under study

About Antineoplastic Agents Clinical Trials

Looking for clinical trials for Antineoplastic Agents? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Antineoplastic Agents trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Antineoplastic Agents clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Not Applicable

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)Antineoplastic Agents, ImmunologicalVEGFR-TKI
Federation Francophone de Cancerologie Digestive300 enrolled83 locationsNCT07124858
Recruiting
Not Applicable

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

Arterial Occlusive DiseasesCardiovascular DiseasesCoronary Disease+22 more
Fondazione Ricerca e Innovazione Cardiovascolare ETS576 enrolled1 locationNCT06535568
Recruiting
Phase 1

A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects

Antineoplastic AgentsGastrointestinal NeoplasmsFecal Microbiota Transplantation (FMT)+1 more
Second Affiliated Hospital, School of Medicine, Zhejiang University90 enrolled1 locationNCT07319364
Recruiting

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

CarcinomaCarcinoma, Renal CellNeoplasms+10 more
Jinling Hospital, China39 enrolled1 locationNCT06676527
Recruiting
Phase 1

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

MelanomaNeoplasmsNeoplasms by Site+7 more
Yana Najjar50 enrolled2 locationsNCT04572451
Recruiting
Not Applicable

Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)

CardiotoxicityCancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)Elderly+1 more
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León514 enrolled14 locationsNCT03711110
Recruiting
Phase 2

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Non-small Cell Lung CancerAntineoplastic AgentsEGFR+5 more
Peng Zhang60 enrolled1 locationNCT06755684
Recruiting
Phase 2

Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma

NeoplasmsAntineoplastic AgentsCarcinoma, Squamous
The First Affiliated Hospital of Guangzhou Medical University25 enrolled1 locationNCT05964101